Alleviant Medical secures $90m to launch pivotal aortic stent trial
Texas medical device firm Alleviant Medical has secured $90m to fund a second pivotal trial of the company’s heart system …
Post
-
-
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for …
-
Clinical research survey results: The key pressures for SMEs and business outlook
The pharma sector is at a crossroads, with major challenges for small and medium-sized businesses driving clinical research. However, there …
-
As avian influenza A(H5N1) concerns continue, mRNA vaccines offer great potential
With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health …
-
Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg …
-
BlueRock accelerates Parkinson’s disease therapy to Phase III
US-based Bayer subsidiary BlueRock Therapeutics has accelerated bemdaneprocel, its investigational cell therapy candidate for Parkinson’s disease, to Phase III trials …
-
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting at …
-
Enhancing patient engagement and outcomes in the NHS
Medication non-adherence is an enduring issue in the UK healthcare system, costing the NHS a staggering £930 million annually.[i] Despite …
-
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues …
-
Broader population could benefit from Novartis spinal muscular atrophy treatment
Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy – …
-
Onera’s validation trial of home polysomnography sleep device succeeds
Dutch remote monitoring and sleep aid company, Onera Health’s wireless, patch-based, type-II home-polysomnography system has proven to be as beneficial …
-
Verismo doses first subject in Phase I trial of SynKIR-310
Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed …
-
2024 was a record year for obesity trials and 2025 is already poised to take over
There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of …
-
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its …
-
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial
Canadian biotech ProMIS Neurosciences has initiated a Phase Ib trial of its lead therapeutic candidate, PMN310, designed to treat Alzheimer’s …
